Tag: SUS liabilities

Insights

ANS Unanimously Rejects Hapvida Appeal, Ordering Full Reversal of 2024 Desenrola Gain

5 de December de 2025

The most comprehensive resource for portfolio managers and investors focused on emerging markets — with a special emphasis on Brazil. In-depth analysis, curated insights, and data-driven perspectives on Latin America’s largest economy.

Navigate

Home
About us
Insights
Compliance
Contact

Follow

X
Instagram
LinkedIn
Facebook

Tag: SUS liabilities

ANS Unanimously Rejects Hapvida Appeal, Ordering Full Reversal of 2024 Desenrola Gain